Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Marinus (MRNS) Stock Price & Analysis
1,120 Followers
MRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.10 - $11.26
Previous Close$1.42
Volume208.69K
Average Volume (3M)1.15M
Market Cap
$77.73M
Enterprise Value$37.95M
Total Cash (Recent Filing)$113.25M
Total Debt (Recent Filing)$73.47M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 08, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding54,933,774
10 Day Avg. Volume928,037
30 Day Avg. Volume1,153,632
Standard Deviation0.28
R-Squared0.04
Alpha-0.00434
Financial Highlights & Ratios
Price to Book (P/B)4.36
Price to Sales (P/S)2.36
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.43
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$5.33Price Target Upside276.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Marinus News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPreliminary EEG analyses indicated patients receiving GNX demonstrated durable reductions in seizure burden through 36 hrs with an 88% median reduction.
Financial StabilityThe company has implemented cost reduction plans and ended 1Q24 with ~$110M in cash, which management expects will be sufficient to support operations into 1Q25.
Regulatory ProgressThe USPTO has granted a new patent for the treatment of TSC with ganaxolone, which provides protection through 2040.
Bears Say
Clinical Trial ResultsThe Phase 3 RAISE trial of IV ganaxolone in refractory status epilepticus did not meet the predefined early stopping criteria of the interim analysis.
Commercial OutlookThe lack of benefit on progression to IV anesthesia suggests a tough regulatory path and unclear commercial success.
Financial PerformanceFollowing the interim miss in RAISE and IV ganaxolone's future looking bleak, Marinus will be reviewing cost-cutting measures.
---
Ownership Overview
34.05% Insiders
18.25% Mutual Funds
6.46% Other Institutional Investors
41.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNS FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $1.10 and its highest was $11.26 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is Aug 08, 2024 which is in 13 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on May 08, 2024. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.017.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -$0.59.
How many shares outstanding does Marinus have?
Marinus has 54,931,040 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went down -8.917%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is GMT Capital Corp. It holds Marinus’s shares valued at 15M.
---
Marinus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.33 (276.68% Upside)
$5.33 (276.68% Upside)
Blogger Sentiment
Bullish
MRNS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 393.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.64%
12-Months-Change
Fundamentals
Return on Equity
-423.43%
Trailing 12-Months
Asset Growth
-39.44%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Earnings Call
Q4 2024
0:00 / 0:00
---
MRNS Stock 12 Month Forecast
Average Price Target
$5.33
▲(276.68% Upside)
Technical Analysis
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
18/36 ratings generated profit
1 Year Average Return
+6.02%
reiterated a buy rating last month
Copying Michael Higgins's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +6.02% per trade.
---